Calithera Biosciences Announces CB-708 Preclinical Data Presentation at the AACR Annual Meeting 2019
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preclinical data highlighting the potential of CB-708, the company's orally bioavailable CD73 inhibitor will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2019, taking place March 29 to April 3, 2019 in Atlanta, Georgia.
Details for the presentation are as follows:
Title: Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73
Presenter:Clarissa Lee, Calithera Biosciences
Session Title: Novel Immunomodulatory Agents 2, Abstract #4134
Session Date and Time: Tuesday April 2, 20191:00 p.m. ET - 5:00 p.m. ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25, Board 8
CD73 is an enzyme in the tumor microenvironment that produces adenosine, a powerful inhibitor of immune function in tumors. CD73 is expressed across a wide range of tumor types and tumor infiltrating leukocytes. Expression of CD73 often correlates with poor prognosis in patients with cancer. Blockade of adenosine production by CD73 inhibition is expected to reverse immunosuppression in the tumor microenvironment and enhance the immune system's ability to fight the cancer. CB-708 is an orally bioavailable small molecule inhibitor of CD73.
Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer and other life-threatening diseases by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism. Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the timing of Calithera's clinical trials, the review, registration and approval of CB-708 by the FDA, and the safety and efficacy of CB-708. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
SOURCE: Calithera Biosciences, Inc.
Source: Calithera Biosciences, Inc.